The Recall Desk
HighFDA (Drugs)·D-0113-2026·Announced 2025-11-05

[pending] R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chlorid

Pending LLM rewrite. Source: FDA_DRUG D-0113-2026.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: Pending LLM scoring against the rubric.

Plain-English summary

Presence of Particulate Matter

The recalled product

Product
R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chloride Solution, Total Volume: 50 mL syringe. INJECTION FOR PERIARTICULAR USE; Not for IV Use. THIS IS A COMPOUNDED DRUG. QuVA Pharma, 1075 West Park One Drive, Suite 100, Sugar Land,
Manufacturer
QuVa Pharma, Inc.

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (20)

  • Lot
  • expiry: 10149179
  • exp 10/15/2025
  • 10149503
  • exp 10/13/2025
  • 10149504
  • 10149657
  • exp 10/16/2025
  • 10149658
  • 10149659
  • 10150137
  • exp 10/23/2025
  • 10150138
  • 10150139
  • 10150140
  • 10149729
  • 10149730
  • 10149732
  • 10149733
  • 10149737

Distribution

Distributed nationwide across the United States.